Shady Grove Fertility (SGF) New York Announces Nine Upcoming Patient Education Events in its New Manhattan Location, Hosted by Drs. Anate Brauer and…

January 8, 2020 medical

Shady Grove Fertility (SGF), home to 85,000 babies born and 8,000 babies born from donor egg treatment, is opening its doors to introduce its SGF New York physicians and discuss how SGF New York helps individuals and couples start or grow their families.

NEW YORK, Jan. 8, 2020 /PRNewswire-PRWeb/ -- Physicians from Shady Grove Fertility (SGF) New York will host nine free educational events this January, February, and March, including three fertility seminars, three donor egg treatment seminars, and three egg freezing seminars.

Attendees can unwind with refreshments during informal, physician-led seminars and question-and-answer sessions with leading experts in infertility.

SGF New York's fertility seminars will cover infertility basics, including menstrual cycle warning signs, common causes of infertility, how infertility is diagnosed and recommendations for when to see a fertility specialist, success rates, financial programs, treatment options, and much more. SGF New York's fertility seminars are free and include a complimentary physician consult that can be scheduled onsite.

SGF New York's donor egg treatment seminars will provide in-depth look into SGF's internationally renowned Donor Egg Treatment Program, the largest program in the nation. SGF, home to more than 8,000 babies born from donor egg treatment, is one of only a few centers in the nation that recruits, selects, and prescreens (medically, psychologically, and genetically) its own ready-to-cycle egg donors prior to making them available on their donor registry. Further, SGF offers exclusive 100% refund guarantee programs not only for IVF but donor egg treatmenta significant differentiator among other programs in the area. All attendees will receive a complimentary physician consult and one lucky attendee will receive $1,000 off a future donor egg treatment at SGF New York.

SGF New York's egg freezing seminars will offer attendees a deep dive into SGF's track record with egg freezing, a fertility-preserving option that's growing in popularity at an unprecedented 20 percent per year, nationally, with even higher growth rates in New York City and surrounding areas. SGF holds the spot as one of the top five egg freezing programs in the U.S., and the number of women choosing egg freezing at SGF continues to rise. The seminar will cover SGF's success rates, with SGF being one of only a few centers in the nation with published success rates for women who return to use their frozen eggs. In addition, the seminar will cover what to expect during fertility testing to determine candidacy for egg freezing, what to expect during an egg freezing cycle, financial programs, SGF's refund guarantees for egg freezing, and much more. All attendees will be entered into a raffle where one lucky attendee will receive $1,000 off a future egg freezing treatment cycle at SGF New York.

All SGF New York seminars will be hosted in their new 15,300 square foot space in New York City, conveniently located at 110 East 60th Streetminutes from nine NY subway stations providing easy access from all boroughs as well as Westchester, Long Island, and Connecticut, and steps from Bloomingdales, Rockefeller Center, Central Park, and The Plaza Hotel.

The SGF New York location is home to physician offices for patient consultations, SGF's ninth embryology lab, a spacious operating room, embryo transfer room, and recovery bays. Patients benefit from having an onsite dedicated andrology laboratory for sperm preparation and an onsite endocrinology lab for processing bloodwork.

Services available in SGF New York include fertility testing and diagnosis, including semen analysis; non-invasive fertility options such as ovulation induction and intrauterine insemination (IUI); in vitro fertilization (IVF); donor egg treatment; preimplantation genetic testing; fertility preservation through egg freezing; and LGBTQ family building.

Story continues

While all SGF in-person and online events are complimentary, interested parties must register to attend by visiting the SGF calendar of events.

Dr. Anate Brauer earned her medical degree from the George Washington University School of Medicine. She completed her residency training in obstetrics and gynecology at New York Presbyterian Hospital-Weill Cornell Medical Center, and her fellowship training in reproductive endocrinology and infertility at Weill Cornell Medical College in New York, NY. Dr. Brauer is board certified in obstetrics and gynecology and reproductive endocrinology and infertility.

Dr. Singer earned his medical degree from the Sackler School of Medicine and his Master of Business Administration in Health Care Management from Hofstra Zarb School of Business. He completed his residency training in obstetrics and gynecology at Lenox Hill Hospital in New York, NY, where he also served as Chief Resident, and his fellowship training in reproductive endocrinology and infertility fellowship at Weill Cornell Medical College in New York, NY. Dr. Singer is board certified in obstetrics and gynecology and reproductive endocrinology and infertility.

To make an appointment in New York City, call 212-203-4826 or submit this brief form.

To schedule an appointment at any of SGF's other 35 domestic locations, call the SGF New Patient Center at 888-761-1967.

About Shady Grove Fertility (SGF) SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 36 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

SOURCE Shady Grove Fertility

Go here to read the rest:
Shady Grove Fertility (SGF) New York Announces Nine Upcoming Patient Education Events in its New Manhattan Location, Hosted by Drs. Anate Brauer and...

Embryology

Assisted Reproductive Technology Market would Witness an Annual Increase of Around 6.3% in 2020-2025 – MENAFN.COM

January 8, 2020 medical

(MENAFN - Market Research HUB) Reproduction segment is currently blooming. The major factor responsible for its growth are improved access to fertility clinics and fertilization technology advancements. Different organizations have come forward to encourage people to avail reproductive assistance services. Angels of Hope Foundation, BabyQuest Foundation and Pay-it-Forward Foundation are some of the organizations in US that offer grants to make fertility treatment affordable as it is cost-intensive which discourages the general public. Reproductive outcomes from such services have been positive. This increases the adoption rate of assistive reproductive technologies like IVF and IUI. Technologies have significantly increased the number of treatments that are available for infertility.Modern lifestyle induces productivity issuesIn many economies across the globe, same sex marriages are made legal. Such marriages are eyed as prominent revenue source for the global assistive reproductive technology market. Latest Fact.MR report forecasts that the revenue of assistive reproductive technology will increase by 6.3% by the end of 2020.Modern lifestyle has induced stress in people. This adversely effects the reproductive capacity in men and women, compelling them to divert towards assistive reproductive technologies. Centers for Disease Control and Prevention (CDC) give the data that 82% ART cycle induced pregnancies are based on use of fresh non-donor eggs. The major factor driving this rate is the desire to have a child with eggs form one person. Fresh non-donor eggs are trending as the medium for using assistive technology. It is primarily used by women below the age of 35. Major factors like late family planning and increase in prevalence of chronic diseases such as cancer cause infertility issues. Medical freezing is getting recommended by medical professionals for women to reduce the risks of infertility.Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4393Employers offer perks and incentives to employeesMajor employers are addressing infertility issues in their employees. They have come up with perks and incentives to encourage employees to store eggs so that they do not undergo infertility issues in future. These factors are expected to surge the demand for frozen non-donor procedures. Assistive reproductive technology is used to treat infertility using many treatment cycles, which makes the treatment very expensive.Fertility clinics have identified the scope of opportunities in treatment of productivity issues. They have introduced one stop solutions that include diagnostic as well as the treatment. Major stake holders are investing towards development of embryology labs that are used to ensure safe and efficient gamete handling. Medical professionals are preferring fertility clinics of treatment as these spaces offer quality service and are laced with advanced technologies. Fact.MR report predicts that fertility clinics can generate US$16.8Bn revenue by the end of the year 2020.Different attitude is adopted towards assisted reproductive technology in different regions. This happens because such technologies get different implementation in terms of reimbursement facilities, patient outcomes and cost in different regions. Fact.MR report highlights the fact the 53% of the Netherland's population ops for quality reproductive treatments and chooses to even go abroad for it. Cross-border reproductive care is highly popular in European countries.Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=4393

MENAFN0801202000703446ID1099523637

Embryology

Fertility Clinics Scoring Well in Assisted Reproductive Technology Market – Voice of Reports

January 8, 2020 medical

Reproduction segment is currently blooming. The major factor responsible for its growth are improved access to fertility clinics and fertilization technology advancements. Different organizations have come forward to encourage people to avail reproductive assistance services. Angels of Hope Foundation, BabyQuest Foundation and Pay-it-Forward Foundation are some of the organizations in US that offer grants to make fertility treatment affordable as it is cost-intensive which discourages the general public. Reproductive outcomes from such services have been positive. This increases the adoption rate of assistive reproductive technologies like IVF and IUI. Technologies have significantly increased the number of treatments that are available for infertility.

Modern lifestyle induces productivity issues

In many economies across the globe, same sex marriages are made legal. Such marriages are eyed as prominent revenue source for the global assistive reproductive technology market. Latest Fact.MR report forecasts that the revenue of assistive reproductive technology will increase by 6.3% by the end of 2020.

Modern lifestyle has induced stress in people. This adversely effects the reproductive capacity in men and women, compelling them to divert towards assistive reproductive technologies. Centers for Disease Control and Prevention (CDC) give the data that 82% ART cycle induced pregnancies are based on use of fresh non-donor eggs. The major factor driving this rate is the desire to have a child with eggs form one person. Fresh non-donor eggs are trending as the medium for using assistive technology. It is primarily used by women below the age of 35. Major factors like late family planning and increase in prevalence of chronic diseases such as cancer cause infertility issues. Medical freezing is getting recommended by medical professionals for women to reduce the risks of infertility.

Request for the Sample of the Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=4393

Employers offer perks and incentives to employees

Major employers are addressing infertility issues in their employees. They have come up with perks and incentives to encourage employees to store eggs so that they do not undergo infertility issues in future. These factors are expected to surge the demand for frozen non-donor procedures. Assistive reproductive technology is used to treat infertility using many treatment cycles, which makes the treatment very expensive.

Fertility clinics have identified the scope of opportunities in treatment of productivity issues. They have introduced one stop solutions that include diagnostic as well as the treatment. Major stake holders are investing towards development of embryology labs that are used to ensure safe and efficient gamete handling. Medical professionals are preferring fertility clinics of treatment as these spaces offer quality service and are laced with advanced technologies. Fact.MR report predicts that fertility clinics can generate US$16.8Bn revenue by the end of the year 2020.

Different attitude is adopted towards assisted reproductive technology in different regions. This happens because such technologies get different implementation in terms of reimbursement facilities, patient outcomes and cost in different regions. Fact.MR report highlights the fact the 53% of the Netherlands population ops for quality reproductive treatments and chooses to even go abroad for it. Cross-border reproductive care is highly popular in European countries.

Request for Report Methodology: https://www.factmr.com/connectus/sample?flag=RM&rep_id=4393

I am Randy Morales and I focus on breaking news stories and ensuring we (Voice of Report) offer timely reporting on some of the most recent stories released through market wires about Earnings sector.

I have formerly spent over 3 years as a trader in U.S. Stock Market and is now semi-stepped down. I work on a full time basis for News Cast Report specializing in quicker moving active shares with a short term view on investment opportunities and trends.

See the original post:
Fertility Clinics Scoring Well in Assisted Reproductive Technology Market - Voice of Reports

Neuroscience

Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia – A Free Webinar from the Brain & Behavior Research Foundation -…

January 8, 2020 medical

New York, Jan. 08, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation is hosting a free webinar Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia on Tuesday, January 14, 2020, from 2pm to 3pm ET. Gregory A. Light, Ph.D., University of California, San Diego, will be the presenter.

Dr. Light will describe precision medicine trials his team has conducted which significantly reduced symptoms and improved cognitive and daily functioning in patients with chronic psychosis in a real-world setting: a long-term community inpatient facility. They also found that reliable, easy-to-obtain signatures of brain-wave activity recorded at the outset of treatment can be used to identify which patients are most likely to benefit (or not) from treatments. This work ultimately aims to develop personalized biomarker assessment tools to deliver the right treatment to the right person at the right time, to improve outcomes among the millions of people with psychotic disorders, most notably schizophrenia.Jeffrey Borenstein, M.D., President and CEO of the Brain & Behavior Research Foundation and Host and Executive Producer of the public television series Healthy Minds, will be the moderator. Join by phone or on the web at bbrf.org/januarywebinar.

This webinar is part of a series of free monthly Meet the Scientist webinars on the latest developments in psychiatry offered by the Brain & Behavior Research Foundation.

The Brain & Behavior Research Foundation The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia, as well as research on suicide prevention. Since 1987, the Foundation has awarded more than $408 million to fund more than 4,800 leading scientists around the world, which has led to over $4 billion in additional funding. 100% of every dollar donated for research is invested in research grants. BBRF operating expenses are covered by separate foundation grants. BBRF is the producer of the Emmy nominated public television series Healthy Minds with Dr. Jeffrey Borenstein, which aims to remove the stigma of mental illness and demonstrate that with help, there is hope.

Read the original:
Using Tools of Neuroscience to Make Personalized Care a Reality in Schizophrenia - A Free Webinar from the Brain & Behavior Research Foundation -...

Neuroscience

ORYZON to Present at the 3rd Neuroscience Innovation Forum in San Francisco – Yahoo Finance

January 8, 2020 medical

CEO and CMO to present recent progress of vafidemstat

Will also participate in 9th Annual LifeSci Advisors Corporate Access Event 2020

Both events during week of the JP Morgan Healthcare Conference

MADRID, Spain and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces that its management will present recent progress of vafidemstat in central nervous system (CNS) indications at the 3rd Neuroscience Innovation Forum in San Francisco on January 12.

Vafidemstat is in Phase II clinical development in multiple trials. It has demonstrated promise as a safe, well-tolerated and differentiated therapeutic option for treating agitation and aggression, and for treating non-aggressive features of three distinct psychiatric diseases.

Oryzons CEO Dr. Carlos Buesa and CMO Dr. Roger Bullock will make the presentation at the Marines' Memorial Club, a day before the JP Morgan Healthcare Conference. Oryzons presentation will take place at 13:50 PT in Track E in the Room Commandants. At the same event, Dr. Buesa will also participate in the Advances in Alzheimers & Other Cognitive Disorders Panel discussion at 9:30 am PT.

Oryzon will also take part in the 9th Annual LifeSci Advisors Corporate Access Event from January 13 to January 15, 2020 where Oryzons CEO and other management will hold meetings with pharmaceutical companies, institutional investors, analysts and other members of the biotech community at the Sir Francis Drake Hotel (450 Powell Street).

About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzons LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit http://www.oryzon.com.

Story continues

About VafidemstatVafidemstat (ORY-2001) is an oral, CNS optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimers disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed a Phase IIa clinical trial in aggressiveness in patients with different psychiatric disorders (REIMAGINE), with positive preliminary clinical results reported. Additional Phase IIa clinical trials with vafidemstat are ongoing in patients with Mild to Moderate AD (ETHERAL), in aggressiveness in patients with moderate or severe AD (REIMAGINE-AD), and in Relapse-Remitting and Secondary Progressive MS (SATEEN).

About IadademstatIadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (See Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), medulloblastoma and others. Oryzon is currently conducting two Phase IIa clinical trials of iadademstat in combination; the first one in combination with azacitidine in elderly AML patients (ALICE study) and the second one in combination with platinum/etoposide in second line SCLC patients (CLEPSIDRA study). In both studies, preliminary clinical results have been reported.

FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words expects, anticipates, believes, intends, estimates and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisin Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzons securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzons securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.

IR & Media, US & Europe:

Spain:

Oryzon:

LifeSci Advisors LLC

ATREVIA

Emili Torrell

Hans Herklots

Patricia Cobo/Idoia Revuelta

BD Director

+41 79 598 7149

+34 91 564 07 25

+34 93 515 13 13

hherklots@lifesciadvisors.com

pcobo@atrevia.comirevuelta@atrevia.com

etorrell@oryzon.com

See the rest here:
ORYZON to Present at the 3rd Neuroscience Innovation Forum in San Francisco - Yahoo Finance

Neuroscience

AI-based motion-capture system for animals has applications from drug development to ecology – Princeton University

January 8, 2020 medical

A new system that uses artificial intelligence to track animal movements is poised to aid a wide range of studies, from exploring new drugs that affect behavior to ecological research. The approach, shown in the video above, can be used with laboratory animals such as fruit flies and mice as well as larger animals.

The technology developed by Mala Murthy, professor of neuroscience; Joshua Shaevitz, professor of physics and the Lewis-Sigler Institute for Integrative Genomics; Talmo Pereira, graduate student in neuroscience; and then-undergraduate Diego Aldarondo of the Class of 2018 accurately detects the location of each body partlegs, head, nose and other pointsin millions of frames of video.

First, a human experimenter records video of a moving animal. Next, the experimenter directs the systems software to identify a small number of images in which to define body part positions. The system then uses this data set to train a neural network to calculate the location of the points in subsequent frames. The method has recently been extended by Pereira to work not only on videos of a single animal but also on footage of multiple interacting animals, keeping track of animal identities over time.

Funding sources included the National Science Foundation and the National Institutes of Health.

This technology was featured at the annual Celebrate Princeton Innovation (CPI) event in November that highlights the work of faculty and student researchers who are making discoveries and creating inventions with the potential for having broad societal impact. The gathering attracts members of the broader entrepreneurial ecosystem outside the University such as members of the venture capital community, industry, as well as representatives from state and local governments who come to learn about the newest University discoveries and meet the faculty and staff engaged in Princetons innovation initiative.

More here:
AI-based motion-capture system for animals has applications from drug development to ecology - Princeton University

Neuroscience

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week – StreetInsider.com

January 8, 2020 medical

As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot.

If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php

After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com.

See more here:
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week - StreetInsider.com

Neuroscience

Stress-recovery wearable helps the body bounce back with Covestro polycarbonate blend – PRNewswire

January 8, 2020 medical

According to Kathryn Fantauzzi, CEO and co-founder of Apollo Neuroscience, Inc., Apollo is the first wearable that helps the body beat stress by rapidly restoring its natural equilibrium for better sleep, energy and more. She explains that, unlike other wearables, Apollo doesn't just track your bodyit uses vibration to improve your recovery from stress. Originally developed by physicians and neuroscientists at the University of Pittsburgh, Apollo's gentle vibration waves signal safety to the body and improve HRVall through the sense of touch.

Since Apollo is worn on the wrist or ankle, the wearable required a material that withstands everyday productssuch as lotions, perfumes and detergentsas well as drops and daily wear and tear. Makroblend M525 PC+polyester blend from Covestro delivers the toughness and chemical resistance needed to create this durable yet lightweight device.

"Wearables have a long checklist of needs to meet, and it all starts with the right materials," said Doug Hamilton, global healthcare marketing leader, Covestro LLC.

Zachary Williams, market development, Healthcare Polycarbonates, Covestro LLC, added, "Makroblend M525 PC+polyester blend meets two important requirementstoughness and chemical resistanceto help Apollo users find balance with a strong and lightweight device that remains unchanged when exposed to a variety of personal care products."

"Apollo is about empowering people to take control of their healththat's why we chose Covestro as a partner," said John Maholtz, chief operating officer at Apollo Neuroscience. "Covestro's premier materials ensure that Apollo users experience a clean, comfortable and long-lasting product that is just as resilient as they are."

The device works in tandem with an intuitive app which, according to Apollo, features a variety of programs that help users:

Attendees at the following shows will be able to experience first-hand how the Apollo device helps their body adapt to stress:

Learn about what else Covestro has in store for CES: http://www.solutions.covestro.com/en/highlights/campaigns/ces-2020.

About Covestro LLC:Covestro LLC is one of the leading producers of high-performance polymers in North America and is part of the global Covestro business, which is among the world's largest polymer companies with 2018 sales of EUR 14.6 billion. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, construction, wood processing and furniture, electrical and electronics, and healthcare industries. Other sectors include sports and leisure, cosmetics and the chemical industry itself. Covestro has 30 production sites worldwide and employed approximately 16,800 people at the end of 2018.

About Apollo Neuroscience:Apollo is the first wearable that actively helps your body adapt to stress, for better sleep, focus, energy, and more. While other wearables track your body, Apollo empowers you to change it, harnessing the power of neuroscience to deliver gentle waves of vibration shown to rapidly restore your body's natural equilibrium. Apollo works by signaling safety to the body and has been scientifically-validated to improve heart rate variability (HRV), a key metric of health and recovery. Apollo has been evaluated in university-led trials and has been tested by over 2,000 users. For more information, visit http://www.apolloneuro.com.

Find more information at http://www.covestro.usorwww.solutions.covestro.com/en/materials/plastics.

Forward-Looking StatementsThis news release may contain forward-looking statements based on current assumptions and forecasts made by Covestro AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Covestro's public reports which are available at http://www.covestro.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Makroblend is a registered trademark of the Covestro Group.

This press release is available for download from our website. Click here to view all our press releases.

Editor's Note: Follow news from Covestro on Twitter: https://twitter.com/CovestroUS

Contact John Skabardonis Telephone +1 412 413 5444 Email John.Skabardonis@covestro.com

SOURCE Covestro LLC

http://www.covestro.com/en

See original here:
Stress-recovery wearable helps the body bounce back with Covestro polycarbonate blend - PRNewswire

Neuroscience

R&D alliance between Harvard and Deerfield announces first project agreement – Harvard Office of Technology Development

January 8, 2020 medical

All News

January 08, 2020

Profs. Lauren Orefice and David Ginty discuss their research in more detail in a Harvard Gazette Q&A. (File photo: Harvard OTD.)

Cambridge, Mass. January 8, 2019 Lab1636, the R&D alliance between Harvard University and Deerfield Management Company, announced today its first project agreement to advance Harvard researchers innovations toward the development of novel therapeutics. Lab1636 has committed to a first project out of the laboratory of David Ginty, PhD, the Edward R. and Anne G. Lefler Professor of Neurobiology in the Blavatnik Institute at Harvard Medical School (HMS) and a Howard Hughes Medical Institute Investigator.

Launched in March 2019, Lab1636 is a major strategic R&D alliance between Harvard and the healthcare investment firm Deerfield to speed the development and translation of biomedical and life-science innovations into transformative treatments to improve life, health, and medical care. Lab1636 was established with a funding commitment of up to $100 million from Deerfield.

Through this first project, Lab1636 will dedicate focused resources to advancing innovations with great therapeutic potential for patients. Recognized for his labs elucidation of the peripheral nervous system, Ginty seeks to answer fundamental questions in neuroscience relating to how we perceive and respond to our environment. Over the past few years, in particular, significant strides in understanding tactile hypersensitivity have been led by a postdoctoral researcher in his lab, Lauren Orefice, PhD, who is now Assistant Professor of Genetics at HMS and Massachusetts General Hospital. Together, they identified certain compounds that may point the way to a treatment for the touch hypersensitivity experienced by people with autism spectrum disorders.

Its exciting to see discoveries made in my lab being propelled into therapeutic development, where they can benefit from the medicinal chemistry expertise and clinical expertise of other groups, said Ginty. The resources at Harvard to support translational biomedical innovation were really instrumental in helping us advance this work to a jumping-off point, and Im hopeful that further development and clinical testing of the results could make a significant and lasting difference in the lives of patients.

The Ginty Labs research in this area has previously received funding from the federal government and the Simons Foundation, as well as translational research funding from Harvards Blavatnik Biomedical Accelerator and Q-FASTR at HMS. Lab1636 is now poised to validate and expand upon the labs findings, advancing them through late-stage preclinical development.

Were thrilled by the momentum of the Lab1636 alliance so far, said Vivian Berlin, Managing Director of Strategic Partnerships in Harvards Office of Technology Development, which spearheaded the creation of Lab1636 with Deerfield. The collaboration holds great promise to drive rapid innovation across many fields of biomedical science and translate valuable insights into real-world impact.

This is an important milestone for Lab1636 and potentially for people suffering from tactile hypersensitivity, said James E. Flynn, Managing Partner at Deerfield. We look forward to continued progress in Professor Gintys novel work and other exciting developments on the horizon at Harvard.

A private company wholly owned by affiliates of Deerfield, Lab1636 supports Harvard R&D projects through various stages of drug discovery and development, for example enabling studies to explicate the biology of disease, validate therapeutic targets, or achieve a proof-of-concept necessary for filing an Investigational New Drug (IND) application. Harvards R&D projects funded by Lab1636 are initiated by principal investigators from labs across the University and selected by a joint advisory committee.

See also: Harvard professors David Ginty and Lauren Orefice discuss their translational research in a Q&A published today.

All News

Neuroscience

Richest Set of Results to Date Pinpoint Six Genes That Are Linked to Anxiety Disorders – Technology Networks

January 8, 2020 medical

A new collaborative research study of over 200,000 military veterans has discovered six genetic variants that are linked to anxiety.According to statistics from the Anxiety and Depression Association of America, anxiety disorders are the most common mental illnesses in the U.S., affecting a staggering 18.1% of the population each year.

Suffering from an anxiety disorder can have major adverse effects on an individual's quality of life; it may prevent them from being able to socialize, to work, or to engage in relationships, for example. Individuals with an anxiety disorder are three to five times more likely to go to the doctor, and six times more likely to be hospitalized when compared to those who do not suffer from an anxiety disorder.

Anxiety disorders like all psychiatric conditions are complex in their pathophysiology. We don't know exactly what causes them, and therefore, our knowledge on how to treat them is somewhat incomplete. A variety of pharmacological and non-pharmacological treatment options are available; however, they are often limited in success and may only benefit certain individuals.

An increasing amount of research is focusing on the contribution of genetics to the development of mental health conditions. Murray Stein, San Diego VA staff psychiatrist and Distinguished Professor of Psychiatry and of family medicine and public health at UCSD points out "While there have been many studies on the genetic basis of depression, far fewer have looked for variants linked to anxiety, disorders of which afflict as many as one in ten Americans."

Stein is the senior author of a new study, published in the American Journal of Psychiatry, that explores the contribution of certain genetic variants to the development of anxiety disorders.

The research, a genome wide association study (GWAS), analyzed the genomes of approximately 200,000 military veterans from the Million Veteran Program (MVP). From the data, they discovered six genetic variants linked to anxiety. Five were identified in European Americans and one was identified in African Americans.

A selection of these variants has also been previously linked to other conditions such as bipolar disorder, schizophrenia and posttraumatic stress disorder.

"This is the richest set of results for the genetic basis of anxiety to date," said co-lead author Joel Gelernter, the Foundations Fund Professor of Psychiatry, professor of genetics and of neuroscience at Yale. "There has been no explanation for the comorbidity of anxiety and depression and other mental health disorders, but here we have found specific, shared genetic risks."

The MVP offers the opportunity to study a large data set that would otherwise be difficult to gather and collate. Thus far, several studies have utilized the MVP data to make interesting discoveries relating to genetics and psychiatric disorders. Gelernter says, "This is a rich vein we have just begun to tap."

Also of note is the fact that some of the genetic variants identified were linked to genes that regulate hormonal activity, specifically in relation to the sex hormone estrogen. As more females are affected by an anxiety disorder than males, this is an intriguing finding. However, the scientists emphasize that the research sample from the MVP largely consists of men, which could be considered a study limitation.

Nonetheless, the research serves as a contributor to the pool of research expanding our knowledge of the molecular underpinnings of psychiatric disorders.

"One of the goals of this research is to find important risk genes that are associated with risk for many psychiatric and behavioral traits for which we don't have a good explanation," Yale's Daniel Levey, a postdoctoral associate and co-lead author of the study, concludes.

Reference: Leveyet al. (2020). Reproducible Genetic Risk Loci for Anxiety: Results from ~200,000 Million Veteran Program Participants. The American Journal of Psychiatry. DOI:https://doi.org/10.1101/540245.

Visit link:
Richest Set of Results to Date Pinpoint Six Genes That Are Linked to Anxiety Disorders - Technology Networks